SkinBioTherapeutics plc (FRA:5KW)

Germany · Delayed Price · Currency is EUR

0.0500

-0.0030 (-5.66%)

Last updated: Oct 23, 2026, 9:43 PM CEST

Market Cap	17.80M -62.1%
Revenue (ttm)	5.99M +95.2%
Net Income	-523.19K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	0.0530
Previous Close	0.0530
Day's Range	0.0500 - 0.0530
52-Week Range	0.0405 - 0.2300
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 3, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 41

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 5KW

Financial Performance

In fiscal year 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.

Financial numbers in GBP Financial Statements